moneyheap
FTV · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Fortive Corporation (FTV) stock moving?
Fortive beat Q3 2026 estimates on October 28, with revenue of $1.108B versus $1.069B expected and adjusted EPS of $0.77 versus $0.70, and raised full-year adjusted EPS guidance to $3.10-$3.14 from $2.95-$3.05, above the $3.01 consensus. Analysts followed with higher targets: RBC $68 (Sector Perform), Citigroup $71 (Neutral), BNP Paribas $66, and Truist $65 (Hold), so the ratings remain neutral while targets moved up. The stock gapped from $61.62 to a $65.35 open, reached a $67.03 intraday high and closed at $64.11 on 6.3M shares, then rose steadily to a $68.34 close on Nov 4. It fell to $65.42 on Nov 5 on 4.9M shares, recovered to $67.73 on Nov 10, and volume has fallen to 2.7M, so the latest rise lacks the heavy volume of the post-earnings move. The price now sits close to the RBC and Truist targets and below Citigroup's $71, which limits near-term upside on the analyst view. Fluke product launches are minor. A routine CLO share sale on Oct 30 is a small negative signal. Support is near $64-65 and resistance near $68.3-68.9.
News behind the analysis
- Fortive Corporation Reports Third Quarter 2026 Financial Results and Raises Full-Year GuidanceFortive reported Q3 2026 revenue of $1.108 billion and adjusted EPS of $0.77, and raised its full-year 2026 adjusted earnings outlook.
- Fortive Q3 Adj. EPS $0.77 Beats $0.70 Estimate, Sales $1.108B Beat $1.069B EstimateThird-quarter adjusted EPS of $0.77 and sales of $1.108B both came in above analyst estimates of $0.70 and $1.069B.
- Fortive Raises FY2026 Adj EPS Guidance from $2.95-$3.05 to $3.10-$3.14 vs $3.01 EstFull-year 2026 adjusted EPS guidance was raised to $3.10-$3.14, above the prior $2.95-$3.05 range and the $3.01 consensus estimate.
- Fluke Launches New Refrigerated Calibration BathsFortive subsidiary Fluke introduced three refrigerated calibration baths for high-accuracy sensor testing.
- RBC Raises Price Target on Fortive to $68 From $59RBC raised its Fortive price target to $68 from $59 and kept a Sector Perform rating.
- Citigroup Maintains Neutral on Fortive, Raises Price Target to $71Citigroup kept its Neutral rating on Fortive and raised its price target to $71.
- BNP Paribas Adjusts Price Target on Fortive to $66 From $58BNP Paribas raised its Fortive price target to $66 from $58 following the quarterly results.
- Truist Securities Reiterates Hold on Fortive, Raises Price Target to $65Truist kept its Hold rating on Fortive and raised its price target to $65.
- Fluke Unveils New Acoustic Imagers for Industrial MaintenanceFluke introduced the ii1050 and ii1030 acoustic imagers to help maintenance teams find compressed air leaks and mechanical issues.
- Fortive Senior Vice President and Chief Legal Officer Sells SharesChief Legal Officer Peter C. Underwood sold 48,442 shares on October 30, 2026, a routine-sized insider sale in the context of the stock's rally.
About Fortive Corporation
Fortive is an industrial technology company based in Everett, Washington. It owns well-known brands such as Fluke test tools, Tektronix, gas-detection equipment, and Advanced Sterilization Products. After spinning off its precision technologies business (Ralliant) in 2025, it now runs as a smaller, more focused company with two segments.
How it makes money
Fortive sells instruments, sensors, safety equipment and software across two segments. Intelligent Operating Solutions is the larger one, roughly two-thirds of sales: Fluke test and measurement tools, gas detection, and facility and asset management software such as Accruent and Gordian. Advanced Healthcare Solutions, roughly one-third, sells hospital sterilization products and healthcare software. A rising share of revenue is recurring, from software subscriptions and consumables. The company expects 2026 revenue of a little over $4.4 billion, and it has spent about $2.3 billion buying back its own shares since the spin-off.
What usually moves FTV
- Industrial and facilities spending trends
- Data-center, defense and utility demand
- Hospital capital budgets and procedure volumes
- Software and recurring revenue growth
- Share buybacks and acquisitions